JP2003515601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003515601A5 JP2003515601A5 JP2001541898A JP2001541898A JP2003515601A5 JP 2003515601 A5 JP2003515601 A5 JP 2003515601A5 JP 2001541898 A JP2001541898 A JP 2001541898A JP 2001541898 A JP2001541898 A JP 2001541898A JP 2003515601 A5 JP2003515601 A5 JP 2003515601A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- carbon atoms
- independently
- alkyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 description 34
- 150000003839 salts Chemical class 0.000 description 33
- 125000004432 carbon atom Chemical group C* 0.000 description 26
- 125000000217 alkyl group Chemical group 0.000 description 16
- 125000003342 alkenyl group Chemical group 0.000 description 15
- 125000000304 alkynyl group Chemical group 0.000 description 13
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 125000004475 heteroaralkyl group Chemical group 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 229960005520 bryostatin Drugs 0.000 description 4
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- -1 hydroxyl compound Chemical class 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16818199P | 1999-11-30 | 1999-11-30 | |
| US60/168,181 | 1999-11-30 | ||
| PCT/US2000/032896 WO2001040214A1 (en) | 1999-11-30 | 2000-11-30 | Bryostatin analogues, synthetic methods and uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003515601A JP2003515601A (ja) | 2003-05-07 |
| JP2003515601A5 true JP2003515601A5 (enExample) | 2008-01-24 |
Family
ID=22610449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001541898A Pending JP2003515601A (ja) | 1999-11-30 | 2000-11-30 | ブリオスタチンアナログ、合成方法および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6624189B2 (enExample) |
| EP (1) | EP1233956A4 (enExample) |
| JP (1) | JP2003515601A (enExample) |
| AU (1) | AU784589B2 (enExample) |
| CA (1) | CA2393026A1 (enExample) |
| WO (1) | WO2001040214A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7256286B2 (en) * | 1999-11-30 | 2007-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| US20050065205A1 (en) * | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US20080004332A1 (en) * | 2002-03-07 | 2008-01-03 | Alkon Daniel L | Methods for alzheimer's disease treatment and cognitive enhancement |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| PA8580301A1 (es) * | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| US7232842B2 (en) * | 2003-01-10 | 2007-06-19 | Board Of Trustees Of The Leland Stanford Junior University | Kinase inhibitors and associated pharmaceutical compositions and methods of use |
| CA2516393A1 (en) * | 2003-02-20 | 2004-09-02 | Board Of Regents, University Of Texas System | Synthesis of peloruside a and analogs thereof for use as antitumor agents |
| TW201206425A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Treatment of depressive disorders |
| US20070026488A1 (en) * | 2005-07-27 | 2007-02-01 | Targett Nancy M | Biosynthesis of bryostatins by polyketide synthases (PKS) |
| US20070054890A1 (en) | 2005-07-29 | 2007-03-08 | Alkon Daniel L | Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning |
| JP4710698B2 (ja) * | 2006-04-10 | 2011-06-29 | 宇部興産株式会社 | シリルエーテル基を有するβ−ジケトン化合物の製造法 |
| US20080058396A1 (en) * | 2006-07-28 | 2008-03-06 | Alkon Daniel L | Methods of stimulating cellular growth, synaptic remodelling and consolidation of long-term memory |
| CA2659242C (en) | 2006-07-28 | 2015-08-11 | Blanchette Rockefeller Neurosciences Institute | Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory |
| KR20140049054A (ko) * | 2007-02-09 | 2014-04-24 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 두부 외상으로 유발된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련 물질의 치료학적 효과 |
| US8497385B2 (en) * | 2007-08-31 | 2013-07-30 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| US20100280262A1 (en) | 2007-10-19 | 2010-11-04 | Wender Paul A | Bryostatin analogues, synthetic methods and uses |
| US9994585B2 (en) | 2007-12-31 | 2018-06-12 | Aphios Corporation | Transplantation therapies |
| US9107890B2 (en) | 2010-07-08 | 2015-08-18 | Blanchette Rockefeller Neurosciences Institute | PKC activators and anticoagulant in regimen for treating stroke |
| CA2808660A1 (en) | 2010-08-19 | 2012-02-23 | Blanchette Rockefeller Neurosciences Institute | Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators |
| JP6422778B2 (ja) | 2011-11-13 | 2018-11-14 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | Ｐｋｃアクチベーターおよびその組合せ |
| US9163032B2 (en) | 2011-11-13 | 2015-10-20 | Blanchette Rockefeller Neurosciences Insitute | Esters of DCPLA and methods of treatment using the same |
| US9034347B2 (en) | 2011-12-19 | 2015-05-19 | Arphios Corporation | Drug delivery system and method for the treatment of neuro-degenerative disease |
| US9816066B2 (en) | 2012-04-24 | 2017-11-14 | The Regents Of The University Of California | Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters |
| CN109331013B (zh) * | 2012-11-27 | 2022-02-01 | 阿菲欧斯公司 | 苔藓素组合物、其制备方法和用途 |
| HK1218882A1 (zh) | 2012-11-28 | 2017-03-17 | Aphios Corporation | 用於治疗神经退化疾病和其它疾病的组合治疗剂和方法 |
| JP2016516201A (ja) | 2013-03-15 | 2016-06-02 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | 神経保護性ｐｋｃ活性化因子を特定する方法 |
| KR20170031653A (ko) | 2014-04-18 | 2017-03-21 | 뉴로트롭 바이오싸이언스 인크. | 지질 축적 장애의 치료를 위한 방법 및 조성물 |
| JP2018521113A (ja) | 2015-05-11 | 2018-08-02 | アルコン、ダニエル・エル． | ＡｐｏＥ４対立遺伝子の存在を決定した後のＰＫＣ活性化因子を使用した神経変性状態の治療 |
| WO2017053659A1 (en) | 2015-09-23 | 2017-03-30 | Khan Tapan K | Methods for survival and rejuvenation of dermal fibroblasts using pkc activators |
| WO2017062924A1 (en) | 2015-10-08 | 2017-04-13 | Alkon Daniel L | Dosing regimens of pkc activators |
| WO2018034318A1 (ja) | 2016-08-18 | 2018-02-22 | 国立大学法人 奈良先端科学技術大学院大学 | 免疫調節剤 |
| JP7148147B2 (ja) | 2016-10-05 | 2022-10-05 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ブリオスタチン化合物およびその調製方法 |
| AU2018246378A1 (en) | 2017-03-31 | 2019-10-17 | Cellectis Sa | New universal chimeric antigen receptor T cells specific for CD22 |
| WO2018187647A1 (en) | 2017-04-06 | 2018-10-11 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of neurological diseases, disorders, or conditions |
| EP3964210A1 (en) | 2018-05-18 | 2022-03-09 | Neurotrope Bioscience, Inc. | Methods and compositions for treatment of alzheimer's disease |
| US20220133687A1 (en) * | 2020-11-02 | 2022-05-05 | Synaptogenix, Inc. | Methods of treating and preventing neurodegenerative diseases with hgf activating compounds |
| AU2021386370A1 (en) | 2020-11-24 | 2023-06-22 | Lyell Immunopharma, Inc. | Methods for making, compositions comprising, and methods of using rejuvenated t cells |
| CN113773256B (zh) * | 2021-09-16 | 2022-11-18 | 精华制药集团南通有限公司 | 一种琥布宗的合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560774A (en) * | 1982-11-17 | 1985-12-24 | Arizona State University | Macrocyclic lactones |
| US4611066A (en) * | 1984-08-10 | 1986-09-09 | Arizona State University | Bryostatins 4 to 8 |
| US5891870A (en) | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators Q |
| US4833257A (en) * | 1986-07-28 | 1989-05-23 | Arizona Board Of Regents | Compositions of matter and methods of using same |
| AU2337997A (en) | 1996-03-20 | 1997-10-10 | Arizona Board Of Regents, The | Method of treating cancer using c-26 modified bryostatin |
-
2000
- 2000-11-30 EP EP00982401A patent/EP1233956A4/en not_active Withdrawn
- 2000-11-30 JP JP2001541898A patent/JP2003515601A/ja active Pending
- 2000-11-30 CA CA002393026A patent/CA2393026A1/en not_active Abandoned
- 2000-11-30 WO PCT/US2000/032896 patent/WO2001040214A1/en not_active Ceased
- 2000-11-30 US US09/728,929 patent/US6624189B2/en not_active Expired - Lifetime
- 2000-11-30 AU AU19440/01A patent/AU784589B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2198162C2 (ru) | Производное 2-аминопропан-1,3-диола, его фармацевтическое применение и промежуточные продукты для их синтеза | |
| WO2009009501A4 (en) | Non-basic melanin concentrating hormone receptor-1 antagonists and methods | |
| JP2006507220A5 (enExample) | ||
| JP2002539181A5 (enExample) | ||
| JP2005533013A5 (enExample) | ||
| JPH0776174B2 (ja) | 医薬組成物および処置法 | |
| WO2005000353A1 (ja) | 血清コレステロール低下剤或はアテローム性動脈硬化症の予防又は治療剤 | |
| CA2434028A1 (en) | Amino ceramide-like compounds and therapeutic methods of use | |
| JP2022541545A5 (enExample) | ||
| JP2004531478A5 (enExample) | ||
| US4599355A (en) | Treatment of sleep disorders | |
| JPH0273016A (ja) | ５‐ヘテロアリールまたは５‐アリール置換イミダゾ［２，１―ａ］イソキノリンの使用 | |
| EP2139463B1 (en) | Anti-infective agents | |
| JP2005532397A5 (enExample) | ||
| CA2491612A1 (en) | 4-'7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents | |
| CN1466465A (zh) | 肥胖或脂肪肝的预防或治疗药物 | |
| US4647580A (en) | Treatment of Alzheimer's disease | |
| CA2523253A1 (en) | Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists | |
| RU2001104880A (ru) | Пиперазиновые производные, обладающие антидиабетической активностью, способы их получения и содержащие их композиции | |
| CZ20021435A3 (cs) | Pro-léčiva 6-methoxy-2-naftyloctové kyseliny | |
| US8153687B2 (en) | Gallium complexes with polyalcohols and methods of use | |
| US8389732B2 (en) | Synthesis and regioselective substitution of 6-halo- and 6-alkoxy nicotine derivatives | |
| EP0623346A1 (en) | Inhibitor for metastasis of malignant tumor | |
| JP2002520413A5 (enExample) | ||
| JP2565543B2 (ja) | イソオキサゾール化合物およびその用途 |